Skip to content

Dynamics of Dysbiosis in the Skin and Gut Microbiome of Burn Patients

An Exploratory Study on the Dynamics of Microbiome Dysbiosis (Microbial Imbalance) in the Skin and Gut Microbiome of Burn Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07209007
Acronym
BURN-MICRO
Enrollment
600
Registered
2025-10-06
Start date
2025-09-15
Completion date
2030-12-31
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn Injuries, Microbiome, Microbiome Dysbiosis, Skin Disease

Keywords

Burn Injury, Skin Microbiome, Gut Microbiome, Dysbiosis, 16S rRNA Sequencing

Brief summary

This prospective observational cohort study aims to investigate the longitudinal changes in the skin and gut microbiome of burn patients after injury and compare them with healthy controls. Burn injuries are known to induce systemic physiological and immune responses that may lead to widespread microbial dysbiosis (microbial imbalance) beyond the injured site. However, the dynamics of microbial community changes in both burned and non-burned skin, as well as the gut, remain poorly understood. In this study, a total of 660 participants will be enrolled, including 600 burn patients and 60 healthy controls. For burn patients, skin swabs from burned scars and matched non-burned skin, stool samples, and physiological skin measurements will be collected at multiple time points (baseline, 3 months, 6 months, 12 months, and 24 months). Healthy controls will provide skin and stool samples at baseline only. Microbial profiling will be performed using 16S ribosomal RNA (rRNA) gene sequencing, and functional prediction will be analyzed using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2). Physiological skin-barrier measurements, including transepidermal water loss (TEWL), hydration, pH, erythema, and elasticity, will be assessed using standardized instruments. Blood biomarkers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), will also be measured. The findings of this study will improve our understanding of burn-related microbial dysbiosis, provide insights into microbiome-driven skin-barrier recovery, and inform potential therapeutic strategies for long-term burn care.

Detailed description

This is a prospective, observational cohort study conducted at the Burn Institute of Hallym University Hangang Sacred Heart Hospital. The study aims to characterize temporal changes in the skin and gut microbiome of burn patients compared with healthy controls and to identify potential links between microbiome dynamics, skin-barrier recovery, and systemic immune responses. A total of 660 participants will be enrolled, including 600 burn patients and 60 healthy controls. Burn patients will be followed longitudinally for 24 months, with sample collection and clinical measurements performed at baseline (within 7 days after hospital admission), 3 months, 6 months, 12 months, and 24 months after injury. Healthy controls will provide single-timepoint samples for comparison. Sample Collection Skin Microbiome: Swabs will be collected from burned scars and matched non-burned skin sites. Gut Microbiome: Stool samples will be collected for 16S ribosomal RNA (rRNA) gene sequencing. Skin Physiological Measurements: Transepidermal water loss (TEWL), hydration, erythema, melanin index, elasticity, and pH levels will be measured using standardized instruments (Corneometer®, Tewameter®, Mexameter®, Cutometer®, and pH meter). Blood Biomarkers: Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), interleukin-6 (IL-6), and other systemic inflammatory markers will be analyzed. Microbiome Profiling DNA extraction and 16S rRNA gene sequencing will be performed using Illumina sequencing platforms. Bioinformatic processing will be conducted using the Quantitative Insights Into Microbial Ecology 2 (QIIME2) pipeline. Functional prediction of microbial metabolic pathways will be analyzed with Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2). Beta diversity and alpha diversity indices will be calculated, and taxonomic differences between groups will be assessed using Linear Discriminant Analysis Effect Size (LEfSe). Clinical Relevance Microbiome dysbiosis (microbial imbalance) after burn injury may extend beyond local wounds and affect non-burned skin and the gut, contributing to impaired skin-barrier function, immune dysregulation, and delayed recovery. Understanding these relationships may help develop microbiome-targeted therapeutic interventions, improve wound healing, and optimize long-term patient care.

Interventions

OTHERNo Intervention: Observational Cohort

This is an observational cohort study with no interventions administered. Skin swabs, stool samples, blood samples, and skin physiological measurements will be collected at baseline, 3, 6, 12, and 24 months after burn injury to investigate longitudinal changes in the skin and gut microbiome.

Sponsors

Cho Yoon soo
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Adults aged 19 to 65 years * Patients with partial- or full-thickness burns whose wounds have completely healed following debridement, grafting, or conservative treatment * Ability to understand study objectives and provide written informed consent

Exclusion criteria

* Use of systemic or topical antibiotics, probiotics, steroids, or immunosuppressants within 2 weeks prior to sample collection * Pregnancy or breastfeeding * Chronic skin diseases (e.g., psoriasis, eczema) or systemic illnesses affecting the skin microbiome * Active infections at the sampling site * Any medical condition judged by the investigator to make participation inappropriate

Design outcomes

Primary

MeasureTime frameDescription
Change in Skin Microbiome DiversityBaseline, 3, 6, 12, and 24 months after burn injuryAlpha and beta diversity indices of the skin microbiome will be analyzed using 16S ribosomal RNA (rRNA) gene sequencing and Quantitative Insights Into Microbial Ecology 2 (QIIME2)-based bioinformatics pipeline. Unit of Measure: Shannon diversity index (unitless)
Change in Gut Microbiome DiversityBaseline, 3, 6, 12, and 24 months after burn injuryAlpha and beta diversity indices of the gut microbiome will be analyzed using 16S ribosomal RNA (rRNA) gene sequencing and Quantitative Insights Into Microbial Ecology 2 (QIIME2)-based bioinformatics pipeline. Unit of Measure: Shannon diversity index (unitless)

Secondary

MeasureTime frameDescription
Skin HydrationBaseline, 3, 6, 12, and 24 months after burn injurySkin hydration will be measured using Corneometer® to assess stratum corneum moisture levels. Unit of Measure: arbitrary units (a.u.)
Skin ElasticityBaseline, 3, 6, 12, and 24 months after burn injurySkin elasticity will be measured using Cutometer® to assess biomechanical recovery of scar tissue. Unit of Measure: arbitrary units (a.u.)
Functional Prediction of MicrobiomeBaseline, 3, 6, 12, 24 monthsPredicted microbial functional pathways will be identified using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Unit of Measure: Relative pathway abundance (percentage)
Erythrocyte Sedimentation Rate (ESR)Baseline, 3, 6, 12, and 24 months after burn injuryESR will be measured from peripheral blood samples to assess systemic inflammation. Unit of Measure: millimeters per hour (mm/hr)
Serum C-Reactive Protein (CRP) ConcentrationBaseline, 3, 6, 12, 24 monthsSerum CRP concentration will be measured as a systemic inflammatory biomarker. Unit of Measure: milligrams per liter (mg/L)
Transepidermal Water Loss (TEWL)Baseline, 3, 6, 12, 24 monthsTEWL will be measured using Tewameter® to assess skin barrier integrity. Unit of Measure: grams per square meter per hour (g/m²/h)

Countries

South Korea

Contacts

Primary ContactYoon Soo Cho, MD, PhD
yschorm@hallym.ac.kr+82-2-2639-5730
Backup ContactYeonGyun Jung, PhD
jyg1076@gmail.com+82-2-2639-5730

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026